A urine cancer risk test could improve early cancer risk assessment, but India faces clinical validation and screening challenges.
The narcolepsy drug Orzeyful has entered the US market, giving Takeda a new commercial opportunity in sleep disorder treatment following final regulatory clearance.
US FDA approval for Indian pharma companies faces fresh regulatory questions following the shelving of a special accelerated drug-review program.
Alkem Labs continues to strengthen its domestic business as pricing pressure, regulatory delays, and slower contract manufacturing growth weigh on its US operations.
Drug-resistant TB in India remains a treatment challenge despite improving tuberculosis outcomes, according to WHO's latest report.
Zealand Pharma is seeking pharmaceutical partnerships for its rare disease assets as it shifts investment towards obesity drug development.
India is considering changes to attract multinational pharmaceutical companies for early-stage drug research while protecting clinical trial participants.
Lupin's ranibizumab biosimilar enters Europe through Sandoz, expanding the Indian drugmaker's international ophthalmology business.
Alembic Pharmaceuticals is banking on its upcoming US drug launch pipeline to sustain strong growth as competition and pricing pressure reshape the generics market.
Amgen's experimental drug dazodalibep has delivered positive Phase 3 results, offering new possibilities for Sjogren's disease treatment.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
